Geode Capital Management
BJDX icon

Geode Capital Management’s Bluejay Diagnostics BJDX Stock Holding History

Geode Capital Management’s Portfolio BJDX Stock Details BJDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,127
Closed -$51.8K – 4458
2026
Q1 		$51.8K Buy
28,127
+25,563
+997% +$63.2K ﹤0.01% 4306
2025
Q4 		$6.84K Buy
+2,564
New +$16.8K ﹤0.01% 4447
2024
Q4 		– Sell
-101
Closed -$2.56K – 4477
2024
Q3 		$2.56K Buy
+101
New +$7.23K ﹤0.01% 4528
2023
Q3 		– Sell
-1
Closed -$7.86K – 4768
2023
Q2 		$7.86K Hold
1
– – ﹤0.01% 4728
2023
Q1 		$11.9K Hold
1
– – ﹤0.01% 4758
2022
Q4 		$10K Hold
1
– – ﹤0.01% 4838
2022
Q3 		$23K Buy
+1
New +$34K ﹤0.01% 4893
2022
Q2 		– Hold
0
– – – 4970

Other funds holding BJDX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Geode Capital Management's BJDX Position: Q2 2026 in Review

Geode Capital Management sold out of Bluejay Diagnostics (BJDX) in Q2 2026, closing a stake of 28,127 shares — an estimated $51.8K sold.

Geode Capital Management first reported a position in BJDX in Q3 2022 and held it in 7 quarters. The position peaked at $51.8K in Q1 2026. 8 funds tracked by Wall St. Rank hold BJDX as of Q2 2026.

  • Geode Capital Management reported no remaining Bluejay Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Geode Capital Management sold 28,127 Bluejay Diagnostics shares in Q2 2026, an estimated $51.8K.
  • Geode Capital Management first reported a position in Bluejay Diagnostics in Q3 2022 and held it in 7 quarters.
  • Geode Capital Management's Bluejay Diagnostics position peaked at $51.8K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.